Literature DB >> 21281748

Pharmacology of bisphosphonates.

Serge Cremers1, Socrates Papapoulos.   

Abstract

Four decades of preclinical and clinical research of the pharmacology of bisphosphonates have generated data and concepts that have considerably improved their clinical use. However, despite this progress several pharmacological aspects relevant to bisphosphonate action on bone are still incompletely understood. This is mainly due to the complex, unique pharmacological properties of bisphosphonates. We review here the pharmacokinetic and pharmacodynamic data of bisphosphonates that are relevant for their clinical application and for the potential choice of a given compound, focusing on uncertainties that still exist.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21281748     DOI： 10.1016/j.bone.2011.01.014

Source DB:  PubMed          Journal:  Bone        ISSN： 1873-2763            Impact factor:   4.398


  49 in total

Review 1.  Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.

Authors:  Aline G Costa; Natalie E Cusano; Barbara C Silva; Serge Cremers; John P Bilezikian
Journal:  Nat Rev Rheumatol       Date:  2011-06-14       Impact factor: 20.543

2.  A network modeling approach for the spatial distribution and structure of bone mineral content.

Authors:  Hui Li; Aidong Zhang; Lawrence Bone; Cathy Buyea; Murali Ramanathan
Journal:  AAPS J       Date:  2014-03-27       Impact factor: 4.009

3.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

4.  Removal of pamidronate from bone in rats using systemic and local chelation.

Authors:  R Nicole Howie; Maryka Bhattacharyya; Mohamed E Salama; Mona El Refaey; Carlos Isales; James Borke; Asma Daoudi; Fardous Medani; Mohammed E Elsalanty
Journal:  Arch Oral Biol       Date:  2015-09-07       Impact factor: 2.633

5.  Racial difference in bioavailability of oral ibandronate between Caucasian and Taiwanese postmenopausal women.

Authors:  W-Y Chiu; C-J Lin; W-S Yang; K-S Tsai; J-Y Reginster
Journal:  Osteoporos Int       Date:  2019-10-23       Impact factor: 4.507

6.  Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw.

Authors:  Parish P Sedghizadeh; Allan C Jones; Chris LaVallee; Roger W Jelliffe; Anh D Le; Peter Lee; Andrew Kiss; Michael Neely
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-12-12

7.  Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis.

Authors:  Frederick Wolfe; Marcy B Bolster; Christopher M O'Connor; Kaleb Michaud; Kenneth W Lyles; Cathleen S Colón-Emeric
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

Review 8.  Bisphosphonate treatment for children with disabling conditions.

Authors:  Alison M Boyce; Laura L Tosi; Scott M Paul
Journal:  PM R       Date:  2013-12-22       Impact factor: 2.298

Review 9.  Bone homeostasis and breast cancer: implications for complex therapy and the maintenance of bone integrity.

Authors:  Orsolya Rusz; Zsuzsanna Kahán
Journal:  Pathol Oncol Res       Date:  2012-12-05       Impact factor: 3.201

10.  Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities.

Authors:  Philippe Clézardin
Journal:  Bonekey Rep       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.